Next Article in Journal
Antimicrobial Prophylaxis for Urologic Procedures in Paediatric Patients: A RAND/UCLA Appropriateness Method Consensus Study in Italy
Next Article in Special Issue
Clostridioides difficile Infection Treatment and Outcome Disparities in a National Sample of United States Hospitals
Previous Article in Journal
Categorisation of Antimicrobial Use in Fijian Livestock Production Systems
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 11
Issue 3
10.3390/antibiotics11030295
Review Report
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Brief Report
Peer-Review Record

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

Antibiotics 2022, 11(3), 295; https://doi.org/10.3390/antibiotics11030295
by Ronald G. Hall 2nd 1,*, Travis J. Cole 2, Chip Shaw 2 and Carlos A. Alvarez 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Antibiotics 2022, 11(3), 295; https://doi.org/10.3390/antibiotics11030295
Submission received: 1 February 2022 / Revised: 15 February 2022 / Accepted: 21 February 2022 / Published: 23 February 2022
(This article belongs to the Special Issue Antibiotic Therapy for Clostridioides difficile Infections)

Round 1

Reviewer 1 Report

The manuscript of R.G. Hall et al. titled "The risk of Clostridioides difficile recurrence after initial treatment with vancomycin or fidaxomicin utilizing Cerner Health Facts®" devoted to the problem of Clostridioides difficile infection (CDI) recurrences and effect of vancomycin or fidaxomicin, frequently used for treatment, on recurrence of CDI. The authors used data from the Cerner Health Facts database and statistical analysis. They concluded that fidaxomicin was independently associated with decreased CDI recurrence. Since the data are not particularly novel, the authors presented the study in the form of a brief report.

Although I did not find many major issues, I put here some minor issues and suggestions/typos aimed to improve the manuscript:

Line 2: Italisize Clostridioides difficile.
Line 4: I have doubts about the need to use ® in the title.
Abstract: I suggest stating the aim of the study more clear.
Line 15: I suggest putting the number of patients in the abstract.
Line 25: Omit [1]
Line 32: You started numeration from 2. Where the ref. 1?
Tables 1 and 2: What means numbers? Absolute numbers and percents? Should readers guess?
Tables 1 and 2: Add space between Wan and Walraven.
Line 81: 2.3 comes after 2.1. Did you miss 2.2? Where can I find section 2.2?
Figure 1: What means red and blue colors? Add it to the legend.
Line 183: Omit title of Fig. 2 "Data Extraction Diagram".
Line 193: What means "(1)"?

Author Response

Please see the attached Word file for our responses to your thoughtful comments.

Author Response File: Author Response.pdf

Reviewer 2 Report

The review report is attached.

Comments for author File: Comments.pdf

Author Response

Please see the attached Word file for our responses to your thoughtful comments.

Author Response File: Author Response.pdf

Reviewer 3 Report

I liked the paper. I have some comments:

  • language/editing corrections lines: 6, 43, 46, 165, 177
  • please specify in the text (or ad citations) what do you mean by 'VanWalraven score'
  • how did you decide wheter it is non-severe, fulminant or severe CDI
  • please explain EMR

Author Response

Please see the attached Word file for our responses to your thoughtful comments.

Author Response File: Author Response.pdf

Back to TopTop